Over-expressed JOSD2 was positively correlated with the worse prognosis in hepatocellular carcinoma (Huang et al., 2022), cholangiocarcinoma (CCA) (Qian et al., 2021), and NSCLC (Krassikova et al., 2021). This evidence concerns the gene JOSD2 and hepatocellular carcinoma.